In clinical trials, Exenatide (an agonist of the GLP-1 receptor) administered to patients with type 2 diabetes has shown great promise, resulting in a loss of ~2 kg over 4 weeks and improved glycemic control (Poon et al., 2005). Here, GLP1R is linked to type 2 diabetes mellitus.